Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,800 Million (Mid Cap)
78.00
NA
0.20%
-0.54
9.46%
8.02
Revenue and Profits:
Net Sales:
161 Million
(Quarterly Results - Mar 2026)
Net Profit:
42 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.52%
0%
-9.52%
6 Months
16.23%
0%
16.23%
1 Year
72.97%
0%
72.97%
2 Years
96.08%
0%
96.08%
3 Years
56.61%
0%
56.61%
4 Years
107.85%
0%
107.85%
5 Years
15.43%
0%
15.43%
HitGen, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.26%
EBIT Growth (5y)
32.67%
EBIT to Interest (avg)
5.08
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
0.26
Tax Ratio
19.51%
Dividend Payout Ratio
46.66%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.70%
ROE (avg)
4.35%
Valuation key factors
Factor
Value
P/E Ratio
78
Industry P/E
Price to Book Value
6.54
EV to EBIT
88.55
EV to EBITDA
54.38
EV to Capital Employed
12.95
EV to Sales
18.74
PEG Ratio
0.75
Dividend Yield
0.26%
ROCE (Latest)
14.62%
ROE (Latest)
8.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
160.50
106.70
50.42%
Operating Profit (PBDIT) excl Other Income
43.30
36.80
17.66%
Interest
2.70
2.70
Exceptional Items
-0.30
-2.80
89.29%
Consolidate Net Profit
41.50
27.80
49.28%
Operating Profit Margin (Excl OI)
269.70%
190.70%
7.90%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 50.42% vs -0.65% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 49.28% vs 100.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
427.00
367.50
16.19%
Operating Profit (PBDIT) excl Other Income
116.60
60.10
94.01%
Interest
13.10
13.20
-0.76%
Exceptional Items
-38.70
-14.30
-170.63%
Consolidate Net Profit
49.90
40.90
22.00%
Operating Profit Margin (Excl OI)
142.40%
16.40%
12.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 16.19% vs 11.53% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 22.00% vs 60.39% in Dec 2023
About HitGen, Inc. 
HitGen, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






